Two growing companies, Supernus Pharmaceuticals and Indivior Pharmaceuticals, have
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Supernus and Indivior agree to an all-stock merger creating a $2.2B CNS biopharma led by CEO Jack Khattar, closing Q4 2026.
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster…
Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies.
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and…
Viridian Therapeutics has scored an FDA
Aerospace technology company Redwire—which has partnered with Bristol Myers Squibb and Eli Lilly to test drug manufacturing in…
